Stock Analiz

IMMUTEP Ltd IMMP

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.48Market cap $26M
Open the interactive analysis →

IMMUTEP Ltd (IMMP) is a healthcare company listed in the US with a market value of about $26M. In fiscal year 2025 it had revenue of $7M and net income of -$40M, a net margin of -594.6%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -10% a year.

About IMMUTEP

IMMUTEP is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $2M in 2016 to $7M in 2025, growth of about 18.1% a year. It was profitable in 0 of the last 10 years in our data.

Score: 1.6 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.8
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-158.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)29.3%
Revenue growth (5 yrs, per year)-9.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-627.4%
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$7M$5M$3M$5M$3M$11M$5M$5M$3M$2M
Net income-$40M-$28M-$26M-$22M-$22M-$9M-$13M-$9M-$7M-$46M
Free cash flow-$41M-$23M-$23M-$21M-$13M-$7M-$11M-$6M-$7M-$8M
EPS (diluted)$-5.44$-3.86$-3.59$-3.01$-3.04$-1.25$-1.74$-1.28$-0.98$-6.26
Net margin-594.6%-544.9%-767.2%-476.6%-753.6%-81.6%-244.9%-173.3%-221.9%-3056.6%
ROIC——————————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does IMMUTEP pay a dividend?

Not currently.

Is IMMUTEP a good stock to buy?

We do not give buy or sell advice. IMMUTEP scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.